How to buy Pieris Pharmaceuticals stock | $4.32

Pieris Pharmaceuticals Inc is a biotechnology business based in the US. Pieris Pharmaceuticals shares (PIRS) are listed on the NASDAQ and all prices are listed in US Dollars. Pieris Pharmaceuticals employs 111 staff and has a trailing 12-month revenue of around 0.00.

Pieris Pharmaceuticals stock price (NASDAQ: PIRS)

Use our graph to track the performance of PIRS stocks over time.

Pieris Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$4.32
52-week range	$1.70 - $6.15
50-day moving average	$5.25
200-day moving average	$3.65
Wall St. target price	$8.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.85

Buy Pieris Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Pieris Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pieris Pharmaceuticals price performance over time

Historical closes compared with the close of $4.32 from 2021-10-22

1 week (2021-10-15)	-4.21%
1 month (2021-09-24)	-23.13%
3 months (2021-07-23)	28.19%
6 months (2021-04-23)	89.47%

1 year (2020-10-23)	92.00%
2 years (2019-10-23)	35.85%
3 years (2018-10-23)	4.78
5 years (2016-10-21)	166.67%

Pieris Pharmaceuticals financials

Revenue TTM	$23.7 million
Gross profit TTM	$-14,814,000
Return on assets TTM	-21.64%
Return on equity TTM	-103.55%
Profit margin	-203.73%
Book value	$0.70
Market capitalisation	$300.9 million

TTM: trailing 12 months

Shorting Pieris Pharmaceuticals shares

There are currently 1.1 million Pieris Pharmaceuticals shares held short by investors – that's known as Pieris Pharmaceuticals's "short interest". This figure is 2.1% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Pieris Pharmaceuticals shares can be evaluated.

Pieris Pharmaceuticals's "short interest ratio" (SIR)

Pieris Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Pieris Pharmaceuticals shares currently shorted divided by the average quantity of Pieris Pharmaceuticals shares traded daily (recently around 2.0 million). Pieris Pharmaceuticals's SIR currently stands at 0.55. In other words for every 100,000 Pieris Pharmaceuticals shares traded daily on the market, roughly 550 shares are currently held short.

However Pieris Pharmaceuticals's short interest can also be evaluated against the total number of Pieris Pharmaceuticals shares, or, against the total number of tradable Pieris Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pieris Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Pieris Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0201% of the tradable shares (for every 100,000 tradable Pieris Pharmaceuticals shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pieris Pharmaceuticals.

Find out more about how you can short Pieris Pharmaceuticals stock.

Pieris Pharmaceuticals share dividends

We're not expecting Pieris Pharmaceuticals to pay a dividend over the next 12 months.

Have Pieris Pharmaceuticals's shares ever split?

Pieris Pharmaceuticals's shares were split on a 25:11 basis on 7 December 2014. So if you had owned 11 shares the day before before the split, the next day you'd have owned 25 shares. This wouldn't directly have changed the overall worth of your Pieris Pharmaceuticals shares – just the quantity. However, indirectly, the new 56% lower share price could have impacted the market appetite for Pieris Pharmaceuticals shares which in turn could have impacted Pieris Pharmaceuticals's share price.

Pieris Pharmaceuticals share price volatility

Over the last 12 months, Pieris Pharmaceuticals's shares have ranged in value from as little as $1.7 up to $6.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pieris Pharmaceuticals's is 1.2021. This would suggest that Pieris Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pieris Pharmaceuticals overview

Pieris Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc. ; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc.

Frequently asked questions

What percentage of Pieris Pharmaceuticals is owned by insiders or institutions?
Currently 11.007% of Pieris Pharmaceuticals shares are held by insiders and 47.696% by institutions. How many people work for Pieris Pharmaceuticals?
Latest data suggests 111 work at Pieris Pharmaceuticals. When does the fiscal year end for Pieris Pharmaceuticals?
Pieris Pharmaceuticals's fiscal year ends in December. Where is Pieris Pharmaceuticals based?
Pieris Pharmaceuticals's address is: 255 State Street, Boston, MA, United States, 02109 What is Pieris Pharmaceuticals's ISIN number?
Pieris Pharmaceuticals's international securities identification number is: US7207951036 What is Pieris Pharmaceuticals's CUSIP number?
Pieris Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 720795103